サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795199

めまい治療薬の世界市場

Vertigo Drugs

出版日
ページ情報
英文 267 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
めまい治療薬の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 267 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

めまい治療薬の世界市場は2030年までに26億米ドルに到達

2024年に20億米ドルと推定されるめまい治療薬の世界市場は、2030年には26億米ドルに達し、分析期間2024-2030年のCAGRは4.3％で成長すると予測されます。本レポートで分析したセグメントの1つである末梢めまい治療薬は、CAGR 5.0％を記録し、分析期間終了までに19億米ドルに達すると予測されています。セントラルめまい治療薬セグメントの成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は5億5,540万米ドルと推定、中国はCAGR 8.0％で成長予測

米国のめまい治療薬市場は、2024年に5億5,540万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年にかけてCAGR 8.0％で推移し、2030年には5億4,460万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.4%と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界のめまい治療薬市場- 主要動向と促進要因のまとめ

なぜめまい治療薬はバランス障害の管理に不可欠なのか？

めまいは、めまい、空間見当識障害、平衡感覚障害を特徴とする一般的な神経疾患です。めまいは、前庭機能障害、内耳の炎症、メニエール病、良性発作性頭位めまい症（BPPV）、片頭痛や脳卒中などの神経症状など、さまざまな根本的原因によって生じる。薬物治療は、特に前庭リハビリテーションだけでは不十分な場合に、症状を管理しQOLを改善する上で重要な役割を果たします。めまい治療薬は、前庭信号を抑制し、吐き気を抑え、めまいエピソードの原因となる根本的な炎症や循環の問題に対処するために処方されます。

これらの薬物には、抗ヒスタミン薬、抗コリン薬、ベンゾジアゼピン薬、カルシウム拮抗薬、選択的血管拡張薬などがあります。ベタヒスチンは慢性前庭障害やメニエール病に最も広く使用されている薬剤のひとつであり、メクリジン、プロメタジン、ジアゼパムは急性症状の緩和のために処方されることが多いです。薬理学的反応はめまいの根本原因によって異なるため、正確な診断が非常に重要であり、ある種の薬剤は適用を誤ると症状を悪化させる可能性があります。前庭疾患に対する認識が向上するにつれて、薬物療法を含む正式なケア・パスに組み込まれる患者が増えています。

めまい管理の臨床はどのように進化しているか？

臨床現場では、適切な薬物療法を導くために、めまいの中枢性と末梢性の原因を区別することがますます重視されるようになっています。前庭神経炎や迷路炎に関連しためまいには、副腎皮質ステロイドや抗ウイルス薬が必要な場合があり、片頭痛に関連しためまいは、β遮断薬やカルシウム拮抗薬などの片頭痛予防薬を用いて治療されることが多いです。症状が重い場合や再発を繰り返す場合には、多剤併用療法が行われることもあります。めまい治療薬は、体位調節や慣れ訓練だけでは不十分な場合に、回復を早めるために理学療法を併用することもあります。

特に高齢患者においては、鎮静や耐性などの副作用を最小限に抑えることに特別な注意が払われています。慢性例では、中枢性代償を遅らせる可能性があるため、前庭抑制薬の長期使用は推奨されないです。その代わりに、再燃時には間欠的または短期間の使用が推奨されます。このような処方パターンの変化は、前庭系の可塑性に関するより良い理解と、症状コントロールと長期的なリハビリテーションのバランスをとる必要性を反映しています。

この治療領域では、どのような医薬品のイノベーションが生まれているか？

めまい治療における研究開発活動は比較的緩やかであるが、有効性、発症時間、忍容性の改善に重点が置かれています。急性のめまいエピソードを迅速に緩和するために、吸収速度の速い新しい薬剤製剤が開発されています。特に、吐き気や嚥下困難のある患者に対しては、口腔内分散錠や経皮パッチが検討されています。鎮静剤の副作用を避けるために、前庭選択性を改善した中枢神経系薬剤を再利用する取り組みも進行中です。

持続性めまいに伴う内耳の変性や虚血に対処するために、イオンチャネル調節薬や神経保護化合物を研究している研究者もいます。さらに、制吐剤と前庭抑制剤の併用が、救急医療において相乗効果をもたらすかどうかも評価されています。大規模な技術革新はまだ限定的であるが、デリバリーメカニズムや患者ターゲットの漸進的な改善が、このニッチな治療領域における将来の医薬品開発を形成すると予想されます。

世界的にめまい治療薬の需要が増加している要因は？

めまい治療薬市場の成長は、人口の高齢化、診断意識の向上、耳鼻咽喉科および神経科サービスへのアクセス拡大に関連するいくつかの要因によって牽引されています。高齢者における前庭障害の罹患率の上昇が、症状に特化した治療に対する需要の拡大に寄与しています。プライマリケアにおけるめまいの認知度の向上と、中枢性と末梢性の原因の鑑別の向上が、的を絞った薬理学的介入を後押ししています。ジェネリック製剤の利用可能性は、特に低・中所得地域において、患者のアクセスを拡大しています。めまい治療が外来や遠隔医療に統合されつつあることも、薬理学的レジメンの遵守を促しています。画像診断と前庭検査の進歩により、以前は診断されなかった慢性症例の早期発見と管理が可能になり、それによって支持的薬物療法の市場が拡大しています。

セグメント

タイプ（末梢性、中枢性）、流通チャネル（オフライン、オンライン）

調査対象企業の例

  • AbbVie Inc.
  • AdvaCare Pharma
  • Altamira Therapeutics Ltd.
  • Amneal Pharmaceuticals Inc.
  • Endo International plc
  • Epic Pharma, LLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Indicus Pharma
  • Intas Pharmaceuticals Ltd.
  • Jubilant Pharmova Ltd.
  • Lupin Ltd.
  • Novartis AG
  • Otonomy Inc.
  • Pfizer Inc.
  • Sanofi
  • Sensorion
  • Sound Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Cadila

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革します。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38317

Global Vertigo Drugs Market to Reach US$2.6 Billion by 2030

The global market for Vertigo Drugs estimated at US$2.0 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Peripheral Vertigo Drugs, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Central Vertigo Drugs segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$555.4 Million While China is Forecast to Grow at 8.0% CAGR

The Vertigo Drugs market in the U.S. is estimated at US$555.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$544.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Vertigo Drugs Market - Key Trends & Drivers Summarized

Why Are Vertigo Drugs Critical in Managing Balance Disorders?

Vertigo is a common neurological condition characterized by dizziness, spatial disorientation, and balance disturbances. It arises from various underlying causes including vestibular dysfunction, inner ear inflammation, Meniere’s disease, benign paroxysmal positional vertigo (BPPV), and neurological conditions such as migraines or strokes. Pharmacological treatment plays an important role in managing symptoms and improving quality of life, particularly in cases where vestibular rehabilitation alone is insufficient. Vertigo drugs are prescribed to suppress vestibular signals, reduce nausea, and address the underlying inflammation or circulatory issues contributing to vertiginous episodes.

These medications include antihistamines, anticholinergics, benzodiazepines, calcium channel antagonists, and selective vasodilators. Betahistine is among the most widely used drugs for chronic vestibular disorders and Meniere’s disease, while meclizine, promethazine, and diazepam are often prescribed for acute symptom relief. Accurate diagnosis is critical, as pharmacological response varies depending on the root cause of vertigo, and certain agents may worsen symptoms if misapplied. As awareness of vestibular conditions improves, more patients are being brought into formal care pathways that include drug therapy.

How Is Clinical Practice Evolving in Vertigo Management?

In clinical practice, there is increasing emphasis on differentiating central from peripheral causes of vertigo to guide appropriate drug therapy. Vertigo linked to vestibular neuritis or labyrinthitis may require corticosteroids and antivirals, while migraine-associated vertigo is often treated using migraine prophylaxis drugs such as beta blockers or calcium channel blockers. Multi-drug regimens are occasionally employed when symptoms are severe or recurrent. Vertigo drugs are also being combined with physical therapy to accelerate recovery in cases where positional adjustments or habituation exercises alone are insufficient.

Special attention is being given to minimizing side effects such as sedation and tolerance, especially in elderly patients. In chronic cases, long-term use of vestibular suppressants is discouraged, as it may delay central compensation. Instead, intermittent or short-term use is recommended during flare-ups. This shift in prescribing patterns reflects better understanding of vestibular system plasticity and the need to balance symptom control with long-term rehabilitation.

What Pharmaceutical Innovations Are Emerging in This Therapeutic Area?

R&D activity in vertigo treatment is relatively moderate but focused on improving efficacy, onset time, and tolerability. Novel drug formulations with faster absorption rates are being developed to offer rapid relief in acute vertigo episodes. In particular, orodispersible tablets and transdermal patches are being explored for patients with nausea or swallowing difficulties. Efforts are also underway to repurpose central nervous system agents with improved vestibular selectivity to avoid sedative side effects.

Some researchers are studying ion channel modulators and neuroprotective compounds to address inner ear degeneration or ischemia associated with persistent vertigo. Additionally, combinations of antiemetics and vestibular suppressants are being assessed for synergistic benefit in emergency care settings. While large-scale innovation remains limited, incremental improvements in delivery mechanisms and patient targeting are expected to shape future drug development in this niche therapeutic area.

What Factors Are Driving Increased Demand for Vertigo Drugs Globally?

Growth in the vertigo drugs market is driven by several factors related to aging populations, improved diagnostic awareness, and expanding access to ENT and neurology services. Rising incidence of vestibular disorders among elderly patients is contributing to greater demand for symptom-specific treatments. Improved recognition of vertigo in primary care settings and better differentiation between central and peripheral causes are supporting targeted pharmacological interventions. Availability of generic formulations is expanding patient access, particularly in low and middle-income regions. Increased integration of vertigo treatment into outpatient and telemedicine care models is also encouraging adherence to pharmacological regimens. Advancements in diagnostic imaging and vestibular testing are enabling earlier identification and management of chronic cases that previously went undiagnosed, thereby broadening the market for supportive drug therapies.

SCOPE OF STUDY:

The report analyzes the Vertigo Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Peripheral Vertigo Drugs, Central Vertigo Drugs); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • AdvaCare Pharma
  • Altamira Therapeutics Ltd.
  • Amneal Pharmaceuticals Inc.
  • Endo International plc
  • Epic Pharma, LLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Indicus Pharma
  • Intas Pharmaceuticals Ltd.
  • Jubilant Pharmova Ltd.
  • Lupin Ltd.
  • Novartis AG
  • Otonomy Inc.
  • Pfizer Inc.
  • Sanofi
  • Sensorion
  • Sound Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Vertigo Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Vestibular Disorders and Balance-Related Conditions Drives Demand for Vertigo Therapeutics
    • Aging Population and High Prevalence of Age-Related Vertigo in Elderly Patients Strengthen Market Outlook for Prescription Vertigo Drugs
    • Increased Awareness and Early Diagnosis of Vertigo Syndromes Propel Demand for Targeted Drug Therapies
    • Expansion of ENT and Neurology Services Across Primary Healthcare Networks Accelerates Prescriptions of Vertigo Medications
    • Growing Use of Antihistamines and Anticholinergics as First-Line Treatment Sustains Generic Vertigo Drug Consumption
    • Advances in Vestibular Migraine and Menieres Disease Diagnosis Throw Spotlight on Multi-Drug Therapy Combinations
    • Increasing Preference for Non-Invasive Drug-Based Management Over Surgical Options Enhances Vertigo Drug Market Adoption
    • Rise in Motion Sickness and Travel-Induced Vertigo Symptoms Creates Opportunities for OTC Vertigo Drug Formulations
    • Development of Central-Acting Vertigo Drugs and Vestibular Modulators Expands Treatment Scope in Refractory Cases
    • Growing Investment in Vestibular Research and Drug Repurposing Initiatives Spurs Pipeline Development for Vertigo Therapies
    • Rising Demand for Fast-Acting, Symptom-Relief Medications Drives Innovation in Oral Disintegrating and Liquid Vertigo Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Vertigo Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Vertigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Vertigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Vertigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Peripheral Vertigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Peripheral Vertigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Peripheral Vertigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Central Vertigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Central Vertigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Central Vertigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Vertigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Vertigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Vertigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Vertigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Vertigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Vertigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Vertigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Vertigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Vertigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Vertigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Vertigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Vertigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Vertigo Drugs by Type - Peripheral Vertigo Drugs and Central Vertigo Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Vertigo Drugs by Type - Percentage Breakdown of Value Sales for Peripheral Vertigo Drugs and Central Vertigo Drugs for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Vertigo Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Vertigo Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION